A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians can combine, mix, or adjust the ingredients of a medication — to meet ...

There are many mechanisms at work here, but the blood sugar increase is probably secondary to the weight gain, rather than ...

MASH曾名为非酒精性脂肪性肝炎（NASH），是代谢功能障碍相关脂肪性肝病（MAFLD）的晚期形式。MASH是导致肝脏相关死亡的主要原因，对全球卫生系统造成日益加重的负担。此外，MASH患者，特别是那些具有更多代谢风险因素（高血压、合并2型糖尿病）的 ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Semaglutide, the active ingredient in Ozempic, has shown promising results in weight loss and blood sugar management. But did ...

Ro details dietary choices that may help Wegovy's capacity to regulate appetite and foster a healthier weight as well as ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Unsurprisingly, the patients taking the active semaglutide lost way more weight than their placebo counterparts — but they also experienced dramatic reductions in their pain scales, with an ...